In the press

James Carthew comments on IEM tender result in Investment Week

Biotech trusts top performance charts in February

James Carthew comments on IEM’s tender and low turnout in Linus Uhlig’s article:

“It feels inevitable to us that there will be some shares that were not tendered and the fate of those shareholders and the rump trust is, as yet, unknown. Will Saba have retained a big enough stake to control its future?”

Read the article here